|
Medtronic new product for diabetics
US-based medical technologies company Medtronic has launched a product, which
combines insulin pump with continuous glucose readings and trend graphs.
MiniMed Paradigm Real-time Insulin Pump and Continuous Glucose Monitoring system
allows a patient to make immediate self-management decisions to improve their
glucose control after confirming readings with a fingerstick measurement,
Medtronic business manager Adrian Gut said.
The MiniMed Paradigm Real Time system integrates an external insulin pump with
continuous glucose monitoring (CGM). The system’s glucose sensor takes as many
as 288 daily glucose readings per day, providing nearly 100 times more
information than three daily finger stick readings provided.
"By viewing trends and real-time glucose information, patients can programme
their pump to start or stop insulin delivery upon demand or can eat
carbohydrates to counteract low blood sugar. Timely information coupled with
precise insulin delivery is why this integrated insulin therapy has the
potential to revolutionise diabetes management," Mohan’s diabetes specialities
centre chairman V Mohan said.
(Ref : Economic Times dated October 13, 2006)
Baxter Inc Aligns Indian Operations
Baxter International Inc, a $9.8 billion integrated healthcare
solutions provider of critical therapies, is aligning operations of its Indian
subsidiary with itself. For starters, Baxter will shorten the launch cycle of
its blockbuster global products in India. The company also plans to initiate
global clinical trials and design home dialysis instruments in India.
Baxter's present launch cycle of new products in India is a high
as five years from their original global launch date. "This period will
significantly shrink and our global products will be launched in India much
faster. This is largely due to maturity of the home dialysis market in India,"
said Mr Sanjiv Navangul, business unit director (renal) at Baxter India.
The company may also conduct global trials for future products
in India. "We work with Indian scientists and physicians to develop future
products at our US R&D facility. There's the possibility of working with medicos
here for clinical trials," said Mr. Navangul.
(Ref : Economic Times dated October 13, 2006)
|
